Last reviewed · How we verify
Antiepileptic Drug
Blocks voltage-gated sodium channels
Blocks voltage-gated sodium channels Used for Epilepsy.
At a glance
| Generic name | Antiepileptic Drug |
|---|---|
| Also known as | antiepileptic prophylactic therapy |
| Sponsor | Istituti Clinici Scientifici Maugeri SpA |
| Drug class | Antiepileptic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
This action stabilizes neuronal membranes and prevents the spread of the seizure activity.
Approved indications
- Epilepsy
Common side effects
- Dizziness
- Headache
- Nausea
Key clinical trials
- Relationship Between Neuropathic Pain and Geriatric Assessment Parameters in Patients Aged 80 Years and Older
- Investigating Epilepsy: Screening and Evaluation
- Prospective Study of Postictal Psychotic Symptoms Occuring After Video-EEG Monitoring in Focal Epilepsies (NA)
- Effect of Epilepsy and Antiepileptic Drug Therapy on Gastric Motility and Emptying With Point-Of-Care Gastric Ultrasound
- Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery (PHASE4)
- Neurophysiological Effects of Medication Tapering During Treatment With Spinal Cord Stimulation
- Short Versus Long-term Levetiracetam in Brain Tumors (PHASE3)
- Levetiracetam Versus Phenobarbitone for the Treatment of Neonatal Seizures in a Tertiary Care Hospital. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antiepileptic Drug CI brief — competitive landscape report
- Antiepileptic Drug updates RSS · CI watch RSS
- Istituti Clinici Scientifici Maugeri SpA portfolio CI